Personalised treatment for prostate cancer patients: are we there yet?

Andrew D. Gillen, Iain J. McEwan* (Corresponding Author)

*Corresponding author for this work

Research output: Contribution to journalEditorialpeer-review

1 Citation (Scopus)


Prostate cancer (PCa) is an extremely heterogeneous disease—a small proportion of patients present with rapidly progressing, aggressive disease, referred to as unfavourable-risk PCa; whilst more commonly the disease progresses far more slowly and does not present an immediate health risk (1). This latter category, known as favourable-risk PCa, is not typically treated through intervention—instead, the recommendation for favourable-risk patients is monitoring via active surveillance (AS) (2). Generally, AS strategies are effective (3), although long-term surveillance studies have demonstrated PCa progression, in the form of disease grade reclassification (GR), in around 25% of cases by 10 years post-diagnosis (4,5). This GR risk is increased further in those of African-American race or advanced age (5,6). This propensity for PCa to progress during AS in some patients but not others, and particularly the association of GR with a particular ethnic group, suggests that underlying genetic factors may be important in disease progression, even in favourable-risk cases. Interrogating this heterogeneity provides a promising route to further stratify patients by their risk of disease progression, to better inform clinical assessment and lead to personalised treatment options.
Original languageEnglish
Article number2
JournalAME Medical Journal
Publication statusPublished - Jan 2019


Dive into the research topics of 'Personalised treatment for prostate cancer patients: are we there yet?'. Together they form a unique fingerprint.

Cite this